Boehringer and CDR-Life report data from geographic atrophy treatment trial

Boehringer Ingelheim and CDR-Life have reported positive outcomes from the Phase I clinical trial of BI 771716, a new treatment for geographic atrophy (GA).

BI 771716 is an investigational antibody fragment created to preserve vision in individuals with GA, a severe form of late-stage dry age-related macular degeneration (AMD).